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Background and purpose: Mildronate [3-(2,2,2-trimethylhydrazinium) propionate] is an anti-ischaemic drug whose mecha-
nism of action is based on its inhibition of L-carnitine biosynthesis and uptake. As L-carnitine plays a pivotal role in the balanced
metabolism of fatty acids and carbohydrates, this study was carried out to investigate whether long-term mildronate treatment
could influence glucose levels and prevent diabetic complications in an experimental model of type 2 diabetes in Goto-Kakizaki
(GK) rats.
Experimental approach: GK rats were treated orally with mildronate at doses of 100 and 200 mg·kg-1 daily for 8 weeks.
Plasma metabolites reflecting glucose and lipids, as well as fructosamine and b-hydroxybutyrate, were assessed. L-carnitine
concentrations were measured by ultra performance liquid chromatography with tandem mass spectrometry. An isolated rat
heart ischaemia-reperfusion model was used to investigate possible cardioprotective effects. Pain sensitivity was measured with
a tail-flick latency test.
Key results: Mildronate treatment significantly decreased L-carnitine concentrations in rat plasma and gradually decreased
both the fed- and fasted-state blood glucose. Mildronate strongly inhibited fructosamine accumulation and loss of pain
sensitivity and also ameliorated the enhanced contractile responsiveness of GK rat aortic rings to phenylephrine. In addition,
in mildronate-treated hearts, the necrosis zone following coronary occlusion was significantly decreased by 30%.
Conclusions and implications: These results demonstrate for the first time that in GK rats, an experimental model of type 2
diabetes, mildronate decreased L-carnitine contents and exhibited cardioprotective effects, decreased blood glucose concen-
trations and prevented the loss of pain sensitivity. These findings indicate that mildronate treatment could be beneficial in
diabetes patients with cardiovascular problems.
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Introduction
Diabetes mellitus is a widespread metabolic disease character-
ized by hyperglycaemia and associated with severe complica-
tions, including cardiovascular disease, dyslipidaemia and
increased predisposition to peripheral neuropathy. Risk of
cardiovascular disease is considerably increased in diabetic
patients and novel cardioprotective strategies are being
sought that could target both diabetic and cardiovascular
outcomes (Taegtmeyer et al., 2002; Choy et al., 2008). Among
others, L-carnitine (3-hydroxy-4-N-trimethylaminobutyrate)
was shown to play a pivotal role in both fatty acid and
carbohydrate metabolism (Stephens et al., 2007). In addition
to being an important cofactor in the L-carnitine-mediated
transport of long-chain fatty acids into the mitochondrial
matrix, L-carnitine as a pharmacological agent enhances the
glycolytic processing of carbohydrates (Foster, 2004; Min-
grone, 2004; Stephens et al., 2007). L-carnitine was shown to
increase pyruvate dehydrogenase complex activity in human
mitochondria and this effect was related to the modulation of
the intramitochondrial acetyl CoA/CoA ratio (Uziel et al.,
1988). L-carnitine also stimulated glucose oxidation in intact
fatty acid-perfused rat heart (Broderick et al., 1992). Moreover,
L-carnitine supplementation is believed to be beneficial for
diabetic patients (Mingrone, 2004). More recently, systemic
L-carnitine deficiency caused severe hypoglycaemia in mice
(Kuwajima et al., 2007). Similarly, after treatment with
sodium pivalate, glucose oxidation was increased in
L-carnitine-deficient hearts (Broderick, 2006). Thus, there is
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experimental evidence that the stimulation of glucose
metabolism might be regulated differentially by the availabil-
ity of L-carnitine under certain physiological or pathological
conditions and overall metabolic states.
Mildronate (3-(2,2,2-trimethylhydrazinium) propionate) is
a cardioprotective drug whose mechanism of action is based
on inhibition of the availability of L-carnitine (Dambrova
et al., 2002). Mildronate has been used in combination
therapy for post-infarction chronic heart failure in patients
with type 2 diabetes mellitus (Statsenko et al., 2007). The
cardioprotective effect of mildronate was shown experimen-
tally in vitro in an isolated rat heart infarction model
(Liepinsh et al., 2006), and in vivo in a rat heart infarction
model (Sesti et al., 2006). In addition, mildronate treatment
also improved functional parameters of the heart in rats
with heart failure induced by myocardial infarction (Hayashi
et al., 2000). Recently, we reported that mildronate
decreased L-carnitine and glucose concentrations in blood
plasma, stimulated glucose uptake and glucose metabolism-
related gene expression in mouse heart (Liepinsh et al.,
2008). It was concluded that mildronate induced a decrease
in L-carnitine content, leading to stimulated glucose uptake
(Liepinsh et al., 2008).
The present study was carried out to investigate whether the
decrease in L-carnitine induced by long-term mildronate treat-
ment could influence glucose levels and prevent diabetic com-
plications in the experimental model of type 2 diabetes in
Goto-Kakizaki (GK) rats. These rats exhibit mild hyperglycae-
mia, impaired glucose-induced insulin secretion, marked
glucose intolerance, hepatic glucose overproduction and
peripheral insulin resistance (Bisbis et al., 1993; Gauguier et al.,
1996). Despite the mild hyperglycaemia, both functional and
morphological manifestations of several diabetes complica-
tions have been demonstrated in this model (Suzuki et al.,
1990; Bisbis et al., 1993; Ueta et al., 2005; Azuma et al., 2006).
The present study aimed to evaluate the effects of long-term
mildronate treatment in this model of type 2 diabetes by
measuring the fed- and fasted-state blood glucose levels and
insulin concentrations. To test the effect of mildronate treat-
ment on the fatty acid oxidation rate, we measured plasma
b-hydroxybutyric acid (b-ketone) and free fatty acid (FFA)
concentrations. An isolated GK rat heart ischaemia-
reperfusion model and the constriction of aortic rings were
used to investigate the cardioprotective effects of mildronate in
GK rats after 8 weeks of treatment. In addition, a tail-flick test
was performed to determine the effect of mildronate on the
loss of thermal pain sensitivity as a measure of the functional
manifestation of neurological complications of diabetes.
Methods
Animals and treatment
All animal care and experimental procedures were carried out
in accordance with the guidelines of the European Commu-
nity, local laws and policies and were approved by the Latvian
Animal Protection Ethical Committee, Food and Veterinary
Service, Riga, Latvia. Thirty male GK (10 weeks old, Charles
River Laboratories) and 10 age-matched Wistar rats weighing
200–250 g were housed under standard conditions (21–23°C,
12-h light–dark cycle) with unlimited access to food (R3 diet,
Lactamin AB, Sweden) and water. Wistar rats were used as the
non-diabetic control to evaluate the progression of diabetes in
GK rats.
Rats were adapted to local conditions for 2 weeks before the
start of treatment. Mildronate (100 and 200 mg·kg-1) was
administered p.o. daily for 8 weeks. Control rats received
water. Rats were decapitated 24 h after the last administra-
tion. Blood was collected into EDTA/diamide- and protease
inhibitor (phenylmethylsulphonylfluoride, pepstatin, leupep-
tin, aprotinin)-containing tubes and centrifuged. The
obtained plasma was stored frozen (-80°C) until analysis. The
hearts were excised, washed in cold PBS and used for isolated
heart experiments.
Determination of L-carnitine, g-butyrobetaine and mildronate by
ultra performance liquid chromatography with tandem mass
spectrometry
The determination of L-carnitine, g-butyrobetaine (GBB) and
mildronate concentrations in blood plasma samples was per-
formed by ultra performance liquid chromatography-tandem
mass spectrometry in positive ion electrospray mode as
described previously (Dambrova et al., 2008). In brief, sample
preparation was performed by deproteinization with a
methanol/acetonitrile mixture. Ultra performance liquid
chromatography was carried out using a Waters Acquity
HILIC BEH 1.7 mm 2.1 ¥ 100 mm column. Chromatographic
separation was performed in a 10 mM ammonium acetate (pH
4) and acetonitrile gradient at a flow rate of 0.2 mL·min-1.
Tandem mass spectrometry analysis was performed on a
Micromass Quatro Micro tandem mass spectrometer in posi-
tive ion electrospray mode using multiple reaction monitor-
ing mode with the precursor-to-product ion transition m/z
162.4→m/z 103.0 for L-carnitine, m/z 146.3→m/z 87.9 for
GBB and m/z 147.3 → m/z 58.4 for mildronate. MassLynx 4.1.
software with a QuanLynx 4.1. module (Waters) was used for
data acquisition and processing.
Lipid profile, blood glucose, insulin concentrations and oral
glucose tolerance test
Lipid profile parameters [FFA, low-density lipoprotein (LDL)
and high-density lipoprotein (HDL)-cholesterol] were mea-
sured by IL Laboratories (USA) enzymatic kits. Blood glucose
and b-hydroxybutyrate concentrations were measured using a
MediSense Optium Xceed blood glucose meter and strips.
Plasma insulin concentrations were determined with a RIA kit
(Biotrend, Germany). Fructosamine concentrations were
determined in sodium carbonate buffer (100 mM, pH 10.35)
containing nitro blue tetrazolium chloride (0.25 mM).
Changes in absorption at 550 nm were detected and 1-deoxy-
1-morpholinofructose in bovine serum albumin (40 mg·mL-1)
was used as a standard.
GK rats were subjected to fasting overnight, and then the
oral glucose tolerance test was performed. For oral glucose
tolerance test experiments, rats were given a glucose solution
(2 g·kg-1 of body weight) orally and then blood samples were
drawn at -10 (10 min before test), 15, 30, 45, 60, 120 and
240 min.
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Tail-flick test
Thermal pain sensitivity was determined as changes in reac-
tion latency in control Wistar rats and GK rats, as well as
mildronate-treated GK rats 8 weeks after the p.o. treatment
with mildronate at doses of 100 and 200 mg·kg-1. The spinal
tail-flick response to noxious thermal stimuli was assessed by
a tail-flick apparatus (Model DS20, Ugo Basile, Italy). Briefly,
the rat tail was placed in a groove that contained a slit under
which was located a photoelectric cell. When the heat source
of noxious stimulus was turned on, the heat focused on the
tail, and the animal responded by flicking its tail out of the
groove. Light then passed through the slit and activated
the photocell which, in turn, stopped the recording timer.
The cut-off time was fixed at 20 s in order to avoid damage to
the tail.
Haemodynamic measurements in vivo
Twenty-four hours after the last drug administration, rats
were placed in rodent restrainers on the heating pad (37°C).
To monitor arterial blood pressure and heart rate, the rat tail
was placed in specialized tail cuff with pulse transducer
MLT125/R and the blood pressure was recorded using a Non
Invasive Blood Pressure Controller ML125 connected to Pow-
erLab8 /30 system (ADInstruments) and PC. The pulse was
recorded continuously but blood pressure was sampled peri-
odically for 30 min.
Isolated aortic ring experiments
The experiment was performed as described by Rosen and
Wiernsperger (2006). After removal of the heart and lungs,
the thoracic aorta was rapidly excised, immersed in oxygen-
ated Krebs-Henseleit buffer (pH 7.4, 4°C) and cleaned of con-
nective tissue. The aorta was cut into 3-mm-long aortic rings
that were mounted between two stainless steel hooks in oxy-
genated Krebs-Henseleit buffer (pH 7.4, 37°C). The passive
tension was fixed at 2 g. After a period of equilibration (1 h),
the contractile function was tested twice by the application of
80 mM KCl. Then aortic rings were used to test the contractile
response to phenylephrine (10-9–10-5 M), and after a submaxi-
mal pre-contraction with phenylephrine, a concentration–
response curve to acetylcholine (10-9–10-6 M) was obtained as
a measure of endothelial function. Contractile responses were
evaluated as a percentage of maximal KCl contraction.
Isolated rat heart infarction study
The isolated rat heart experiment was performed essentially as
described earlier (Liepinsh et al., 2006). Hearts were excised
and retrogradely perfused via the aorta at a constant pressure
with oxygenated Krebs-Henseleit buffer at 37°C. The heart
rate, left ventricular end-diastolic pressure and left ventricular
developed pressure (LVDP) were continuously recorded. Coro-
nary flow was measured using an ultrasound flow detector
(HSE) and the PowerLab8/30 system from ADInstruments.
The hearts were perfused for 20 min to stabilize the haemo-
dynamic functions and then coronary flow was occluded for
60 min by constricting threads through a plastic tube. Suc-
cessful occlusion was confirmed by a coronary flow decrease
of about 40%. Reperfusion was achieved by releasing the
threads. At the end of the 150-min reperfusion period, the risk
zone was delineated with 0.1% methylene blue. The hearts
were then sectioned transversely from the apex to the base in
five slices 2 mm in thickness and incubated in 1% triph-
enyltetrazolium chloride in phosphate buffer (pH 7.4, 37°C)
for 10 min to stain viable tissue red and necrotic tissue white.
Computerized planemetric analysis of Sony A700 photo-
graphs was performed using Image-Pro Plus 4.5.1 software to
determine the area at risk and area of necrosis expressed as %
of the left ventricle. The obtained values were then used to
calculate the infarct size as a % of risk area according to the
formula: Infarct size = (area of necrosis/area at risk) ¥ 100%.
Statistical methods
Data are presented as means  SEM. Statistically significant
differences in the mean values were tested by ANOVA and
Tukey’s test, using the GK control (untreated) rats as a refer-
ence group. The differences were considered significant when
P < 0.05. The data were analysed using Graph Pad Prism 3.0
statistical software (Graph Pad, USA).
Materials
Mildronate (3-(2,2,2-trimethylhydrazinium) propionate dihy-
drate) was obtained from JSC Grindeks (Riga, Latvia). Metha-
nol and acetonitrile were purchased from Merck (Darmstadt,
Germany). Acetone, acetic acid, chloroform, diethyl ether,
potassium dihydrogen phosphate, sodium chloride, calcium
chloride, potassium chloride, potassium hydrogen ortho-
phosphate, EDTA, L-carnitine and ammonium acetate were
purchased from Acros Organics (Geel, Belgium). Phenylmeth-
ylsulphonylfluoride, diamide, GBB, pepstatin, leupeptin,
aprotinin, Tris, 1-deoxy-1-morpholinofructose, triphenyltet-
razolium chloride, methylene blue, phenylephrine, acetyl-
choline, sodium carbonate and bovine serum albumin were
obtained from Sigma (USA).
Results
Plasma L-carnitine, GBB and mildronate concentrations
As seen in Table 1, the L-carnitine concentration in GK rat
plasma was 25% lower than that in control (Wistar) rats.
Mildronate treatment at doses of 100 and 200 mg·kg-1 for 8
weeks induced a significant decrease in L-carnitine concentra-
tion for 85% and 95% respectively (Table 1). The GBB plasma
concentration was similar in Wistar and GK control animals,
whereas mildronate treatment induced a fourfold increase in
GBB concentration. At the end of the experiment, the mildr-
onate concentration in treated GK rat plasma reached similar
concentrations for both doses (Table 1).
Blood glucose, fructosamine and insulin concentrations
At the beginning of the experiment (rats 12 weeks of age), the
average glucose concentration in fasted control GK rat blood
plasma was higher than that in Wistar rats (Figure 1). After 4
weeks, the glucose concentration in control GK rats remained
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unchanged, but after 8 weeks it decreased slightly. In Wistar
rats, after 4 and 8 weeks, the fasted plasma glucose levels
remained low. As seen in Figure 1, mildronate treatment
lowered the fasted blood glucose level in GK rats. Thus, after
4 weeks of treatment, a statistically significant blood glucose
lowering effect was observed at a dose of 200 mg·kg-1
(Figure 1). As expected, at the end of the experiment, the
blood glucose concentration in fed GK control rats was sig-
nificantly higher compared with Wistar rats (Table 1). Fur-
thermore, rats treated with mildronate at doses of 100 and
200 mg·kg-1 exhibited dose-dependent decreases in the fed-
stage blood glucose.
As seen in Table 1, the fructosamine concentration in
control GK rats was significantly higher than that in Wistar
rats. In turn, the 8-week mildronate treatment, at either dose,
significantly reduced the fructosamine level in GK rat blood
to values close to those observed in Wistar rats (Table 1). In
contrast, at the end of experiment, the insulin level in control
GK rats was less than half that in Wistar rats, and mildronate
treatment did not induce any significant changes (Table 1).
To evaluate the effect of mildronate on impaired glucose
tolerance in GK rats, the glucose tolerance test was performed
on the day after the final drug treatment. When 2 g·kg-1 of
glucose was used as the oral load in control GK and Wistar rats
after overnight fasting, plasma glucose levels at all time points
in GK control rats were significantly higher than those in
Wistar control rats (data not shown). Mildronate treatment
did not reduce plasma glucose and insulin levels at the mea-
sured time points in the oral glucose tolerance test.
Plasma lipid and b-hydroxybutyrate levels
To characterize the plasma lipid levels, the concentrations of
FFA, HDL-cholesterol and LDL-cholesterol were determined.
The lipid profile of Wistar and GK rats is shown in Table 1. As
seen in the Table, mildronate treatment significantly
increased the HDL-cholesterol concentration in GK rats, but
did not influence the other parameters.
In the beginning of the experiment, the b-hydroxybutyrate
concentration in Wistar and GK rats was similar (Figure 2). In
Wistar rats, the b-hydroxybutyrate concentration did not
Table 1 Effects of mildronate treatment for 8 weeks on some biochemical and diabetes markers in blood plasma
Wistar GK control GK + M100 GK + M200
Fed glucose (mM) 6.0  0.17* 12.7  1.2 10.8  0.68 9.5  0.63*
Fructosamine (mM) 0.41  0.05* 0.68  0.08 0.49  0.06* 0.45  0.06*
Insulin (ng·mL-1) 4.9  0.3* 2.1  0.3 1.7  0.2 2.1  0.3
HDL cholesterol (mg·mL-1) 26.9  0.98 29.1  1.5 32.9  1.3* 32.7  0.98*
LDL cholesterol (mg·mL-1) 35.4  1.5* 39.5  1.3 41.5  2.2 42.9  2.7
FFA (mM) 0.61  0.07 0.54  0.09 0.53  0.08 0.58  0.07
Carnitine (mM) 46.8  5.1* 30.5  1.7 4.5  1.0* 1.7  0.2*
GBB (mM) 1.7  0.2 1.4  0.1 6.4  0.3* 5.5  0.3*
Mildronate (mM) – – 41.9  7.2 45.3  1.0
Treatment for 8 weeks with mildronate (M, 100 or 200 mg·kg-1) induced changes in fed glucose, insulin, FFA, LDL-cholesterol, HDL-cholesterol and fructosamine
concentrations in rat plasma. Each value represents the mean  SEM, n = 8–10 in each group.
GK, Goto-Kakizaki; FFA, free fatty acid; LDL, low-density lipoprotein; HDL, high-density lipoprotein; GBB, g-butyrobetaine.



















Wistar GK Control GK +M100 GK +M200
Figure 1 Effect of 4 and 8 weeks of treatment with mildronate (100
and 200 mg·kg-1) on blood glucose concentrations in fasted Goto-
Kakizaki (GK) rats. Values shown are means  SEM from at least eight


























Wistar GK Control GK +M100 GK +M200
Figure 2 Effect of 4 and 8 weeks of treatment with mildronate (100
and 200 mg·kg-1) on blood-hydroxybutyrate concentrations in fasted
Goto-Kakizaki (GK) rats. Values shown are means  SEM from at least
eight animals. *Significantly different from GK control group (Tukey’s
test P < 0.05).
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change during the course of the experiment. However, in
control GK rats, it was significantly lower than that in Wistar
rats after 4 and 8 weeks. Compared with control GK rats,
mildronate treatment at a dose of 200 mg·kg-1 significantly
decreased the b-hydroxybutyrate concentration in the group
after 4 and 8 weeks of treatment.
Peripheral pain perception
To measure the changes in GK rat peripheral thermal pain
perception, the tail-flick test was performed at the end of the
8-week treatment. As seen in Figure 3, control GK rats exhib-
ited a 40% longer tail-flick latency (12.6 s) than control Wistar
rats (7.2 s). This effect was significantly ameliorated (by 75%)
by the administration of mildronate at a dose of 200 mg·kg-1.
Mildronate treatment at dose of 100 mg·kg-1 did not induce
significant changes in tail-flick latency time in GK rats.
Rat weight and haemodynamic parameters in vivo
As seen in Table 2, the heart rate, systolic blood pressure was
similar across the groups at the end of the experiment. The in
vivo systolic blood pressure was almost the same, but the heart
rate of GK rats was higher than that in Wistar rats; however,
the results were not statistically different. Additionally, mil-
dronate treatment did not affect the haemodynamic param-
eters (Table 2).
Contractile responsiveness of rat-isolated aorta
To measure the contractile responsiveness of vascular tissue,
the vasoconstrictive action of phenylephrine was tested in
aortic rings. Aortic rings from diabetic GK control rats showed
significantly higher sensitivity to phenylephrine, compared
with the aortic rings from the Wistar rats. Accordingly, at
phenylephrine concentrations of 0.01, 0.1 and 1 mM the effect
was higher by 13%, 36% and 29% (P < 0.05) respectively. In
contrast, mildronate treatment at dose of 200 mg·kg-1 for 8
weeks significantly prevented this hypersensitivity to phe-
nylephrine, compared with that in GK controls, the effect of
phenylephrine at concentrations of 0.01 and 0.1 mM being
lower, at 7% and 20% respectively. The endothelium-
mediated vascular relaxation of noradrenaline pre-contracted
mesenteric arterial rings in response to acetylcholine was also
tested. The arterial ring response to acetylcholine was similar
in Wistar and control GK rats, and long-term mildronate
treatment did not induce any changes (data not shown).
Effects in rat-isolated heart infarction model
In isovolumetrically contracting hearts, there were no differ-
ences in control Wistar and GK rat heart rates, peak left
ventricular pressure, LV +dp/dt or LV -dp/dt. In contrast,
coronary flow in GK rat hearts was significantly lower than
that in Wistar rat hearts (Table 3). After 8 weeks of mildronate
treatment at a dose of 200 mg·kg-1, a significant improvement
in coronary flow in GK rat hearts was observed (Table 3).
The anti-infarction effect of mildronate was investigated in
an isolated heart infarction model, using hearts from GK rats.
During occlusion of left coronary artery, the coronary flow in
all experimental groups was decreased for 40% (from 11 to
7 mL·min-1). Moreover, a drop of LVDP, from about 50 to
25 mmHg, was observed. The heart rate during the occlusion
period did not change significantly. During reperfusion, coro-
nary flow, LVDP, dp/dt values were restored to about 80% of
control values. There were no significant differences between
Wistar, GK control and mildronate-treated groups.
Values for the infarction area at risk were similar in hearts of
all experimental groups, and the area at risk in all groups was
about 55% of the area of the left ventricle (data not shown).
The infarct size in control GK and Wistar rat hearts was
similar. As seen in Figure 4, mildronate treatment at doses of
100 or 200 mg·kg-1 decreased the infarct size by 30% (P = 0.03)
and 25% (P = 0.07) of the infarct size in the GK control group
respectively.
Discussion
In the present study, the effects of mildronate on L-carnitine























Figure 3 Effect of 8 weeks of treatment with mildronate (100 and
200 mg·kg-1) on the reaction time in the tail-flick test. Each value
represents the mean  SEM of at least eight animals. *Significantly
different from Goto-Kakizaki (GK) control group (Tukey’s test
P < 0.05).
Table 2 Rat weight and haemodynamic parameters in Wistar and Goto-Kakizaki (GK) rats
Wistar GK control GK + M100 GK + M200
Rat weight (g) 376  25 372  8 378  8 371  42
Systolic blood pressure
(mmHg)
117  4 121  2 114  3 123  4
Heart rate (bpm) 369  9 417  8 391  23 393  11
Effects of mildronate treatment on Wistar and GK rat weight, systolic arterial blood pressure and heart rate. Values are expressed as mean  SEM, n = 8–10 in
each group.
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plications were examined in an experimental model of type 2
diabetes for the first time. The main finding of our study was
that the decreased availability of L-carnitine was accompa-
nied by dose-dependent beneficial effects on fed and fasted
blood glucose concentrations in diabetic GK rats. Further-
more, a protective effect of long-term mildronate treatment
was observed in cardiovascular and pain sensitivity assays.
Our study demonstrated that long-term treatment with mil-
dronate dose- and time-dependently reduced blood glucose in
both the fasted and fed state without increasing insulin levels
(Figure 1, Table 1). In addition, the concentration of fruc-
tosamine or glycated serum protein was reduced to the same
level that was observed in non-diabetic Wistar rats after treat-
ment with mildronate (Table 1), which indicates the effective-
ness of the treatment of the diabetes. Our results are in line
with previous studies that showed the effects of mildronate
on insulin-stimulated glucose metabolism in non-diabetic
mice (Liepinsh et al., 2008). Thus far, the primary mechanism
of pharmacological action of mildronate has been discussed
mainly on the grounds of decreased L-carnitine availability
and the partial inhibition of fatty acid oxidation (Spaniol
et al., 2001; Dambrova et al., 2002; Liepinsh et al., 2006).
However, more recent data provide direct evidence that mil-
dronate also acts as a metabolic modulator that shifts the
energy metabolism substrate preference to glucose in the
heart (Liepinsh et al., 2008). In the present study, we mea-
sured the concentration of b-hydroxybutyrate, the decreased
concentration of which could also be considered a marker of
overall fatty acid oxidation (van Knegsel et al., 2005). The
concentration of b-hydroxybutyrate in control GK rats was
significantly lower than that in Wistar rats, and it was further
decreased after prolonged treatment with mildronate at a
dose of 200 mg·kg-1 (Figure 2). Thus, the beneficial effects of
mildronate treatment in GK rats could be explained by both
the partial inhibition of fatty acid oxidation and an increase
in glucose metabolism.
In the present study, both doses of mildronate significantly
reduced L-carnitine concentrations in the plasma of diabetic
GK rats. After 8 weeks of treatment, a 6–18 fold decrease of
L-carnitine plasma concentrations was observed (Table 1). In
spite of previous reports (Zaugg et al., 2003; Broderick, 2006)
suggesting severe complications in the case of L-carnitine
depletion, we did not observe any problems with motor func-
tion (Rota-rod test, data not shown) or signs of cardiomyopa-
thy in GK rats after treatment with higher doses of mildronate
(Tables 2 and 3). On the contrary, a significant cardioprotec-
tive effect of mildronate was observed. As seen in Figure 4,
mildronate treatment at doses of 100 and 200 mg·kg-1
decreased the infarct size by 30% (P = 0.03) and 25% (P = 0.07)
respectively, while it did not affect the workload. If we
compare the effects of mildronate in diabetic GK and non-
diabetic Wistar rats reported before (Liepinsh et al., 2006), a
comparable cardioprotective effect is observed. Interestingly,
mildronate at a dose of 200 mg·kg-1 induced significantly
better effects on blood glucose concentrations and diabetic
complications, but its protective effect on myocardial infarc-
tion in GK rats was less pronounced than at 100 mg·kg-1.
The effect of long-term treatment with mildronate on the
functional manifestation of diabetes complications was also
assessed. Several studies have demonstrated that impairment
of endothelium-dependent relaxation is associated with dia-
betes (Azuma et al., 2006; Rosen and Wiernsperger, 2006).
Thus, endothelium-dependent vasodilatation is impaired in
diabetic rats, and there is also some evidence that aortic rings
from diabetic rats are more sensitive to the vasoconstrictive
action of phenylephrine (Rosen and Wiernsperger, 2006). In
our study, the contractile responsiveness to phenylephrine
was significantly enhanced in the aortas of GK rats, and this
hypersensitivity was normalized by mildronate at a dose of
200 mg·kg-1. Instead, differences in the response to acetylcho-
line between Wistar and GK rats were not observed, and
mildronate treatment did not induce any changes. The
Table 3 Cardiovascular parameters in isolated hearts from Wistar and Goto-Kakizaki (GK) rats
Wistar GK control GK + M100 GK + M200
Heart index 2.2  0.3 2.2  0.2 2.3  0.4 2.4  0.2
HR (bpm) 237  7 213  8 208  17 256  11
LVP (mmHg) 44  5 52  6 47  5 47  4
CF (mL·min-1) 7.1  0.2* 5.8  0.3 6.3  0.8 6.8  0.2*
+dp/dt (mmHg·s-1) 1365  209 1602  209 1490  96 1456  188
-dp/dt (mmHg·s-1) -945  93 -1032  110 -1015  45 -937  86
Effects of mildronate treatment on heart index (heart weight/body weight), heart rate (HR), left ventricular pressure (LVP), coronary flow (CF) and maximal and
minimal dp/dt in isolated hearts from Wistar and GK rats (untreated (GK control) and treated). Values are expressed as mean  SEM, n = 8–10 in each group.

























Figure 4 Effect of 8 weeks of treatment with mildronate (100 and
200 mg·kg-1) on infarct size in the rat-isolated heart infarction experi-
ment. Each value represents the mean  SEM of at least eight
animals. *Significantly different from Goto-Kakizaki (GK) control
group (Tukey’s test P < 0.05).
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functional impairment of coronary arteries characterized by
significantly lower coronary flow was observed in isolated
hearts from GK rats, in comparison with those from Wistar
rats, but after mildronate treatment at a dose of 200 mg·kg-1,
the coronary flow significantly increased (Table 3). These
findings, together with increased HDL levels, may indicate
that long-term treatment with mildronate prevents endothe-
lial dysfunction in this experimental model of type 2 diabetes.
In previous reports, a peripheral neuropathy characterized
by abnormality in the thermal pain threshold of diabetic GK
rats was associated with the development of diabetes (Suzuki
et al., 1990; Ueta et al., 2005). The loss of thermal response is
dependent on the severity and duration of hyperglycaemia,
and is also a characteristic diabetic complication in patients
(Ueta et al., 2005). Long-term mildronate administration both
controlled hyperglycaemia and prevented the diabetic neur-
opathy (Figure 3). It is very unlikely that mildronate directly
caused neuronal sensitization, as there was no effect on the
tail-flick response after a single administration of mildronate
(data not shown). Hence, our results indicate that mildronate
improves blood glucose control, and might also be beneficial
for the inhibition of neuropathy in type 2 diabetes.
The beneficial effects of L-carnitine supplementation in
animal models of diabetes have been demonstrated (Malone
et al., 1999; Malone et al., 2006; Sena et al., 2008); however,
the effects of L-carnitine and acetyl L-carnitine in healthy
subjects or in type 2 diabetic patients are controversial (Min-
grone, 2004; Gonzalez-Ortiz et al., 2008). The suggested
mechanisms of pharmacological action of L-carnitine are
increased pyruvate dehydrogenase complex activity, a regula-
tion of acetyl- and acyl-cellular trafficking, and changes in the
ascetyl CoA/CoA ratio and expression of key enzymes in gly-
colysis and gluconeogenesis (Uziel et al., 1988; Mingrone,
2004). We have recently shown that decreased L-carnitine
concentrations induced by mildronate treatment brings
about an increase in glucose transporter 4, insulin receptor,
hexokinase II and pyruvate dehydrogenase complex compo-
nent protein expression in heart tissue (Liepinsh et al., 2008).
Thus, taking into account the results of the present study, we
could conclude that both mildronate-induced decrease in
L-carnitine availability and pharmacological supplementa-
tion with L-carnitine can stimulate glucose metabolism, and
that both of these treatments could be effective in diabetes
treatment. Altogether, we conclude that energy metabolism
could be regulated differentially by the availability of
L-carnitine under certain physiological or pathological con-
ditions and the overall metabolic state.
In conclusion, using GK rats as an animal model of type 2
diabetes, we demonstrated that oral treatment with mildr-
onate improved blood glucose levels, protected diabetic rat
heart against ischaemia-reperfusion injury and prevented
diabetes-related endothelial dysfunction and loss of pain sen-
sitivity. The overall beneficial effects of mildronate on type 2
diabetes may be related to the metabolic actions of the drug
mediating a decrease in L-carnitine availability.
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